China approves Bayer blood thinner asundexian

What happened

China's drug regulator approved Bayer's blood thinner asundexian on Monday, the company said. Bayer hopes the drug will offset falling sales of older medicines like Xarelto, which faces cheaper generic competition. China has the world's highest stroke rate, and Bayer had received priority review for the application.

Confirmed

Global impact / market context

Approval gives Bayer a new product in China, the world's second-largest drug market, as it tries to replace revenue lost when Xarelto faced cheaper copies. In a late-stage trial, 6.2% of asundexian patients had another stroke versus 8.4% on placebo.

Analyst inference

Bayer is betting on asundexian against rivals, including Novartis' experimental abelacimab and a joint effort by Bristol Myers Squibb and Johnson & Johnson. The approval may support Bayer's China revenue while generic competition erodes older blood thinner sales.

Analyst inference

What to watch

1. Bayer did not immediately say when asundexian would become available in China, what patients would pay, or forecast sales, leaving launch timing and pricing unclear. Confirmed
2. Watch whether Bayer sets a China launch date and patient price, and whether it announces sales estimates, since those details were not provided in the article. Proposed
3. Watch how asundexian competes with Novartis' abelacimab and the Bristol Myers Squibb and Johnson & Johnson effort, which could affect Bayer's share of China's blood thinner market. Analyst inference

Evidence

• Original source link unavailable